Spots Global Cancer Trial Database for Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Official Title: A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients With HR Myelodysplastic Syndromes or AML Failing HMA-based Therapy
Study ID: NCT05583552
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Royal Adelaide Hospital, Adelaide, , Australia
Royal Brisbane and Women's Hospitals, Brisbane, , Australia
Royal Hobart Hospital, Hobart, , Australia
Linear Clinical Research, Nedlands, , Australia
CHU Nantes - HĂ´tel Dieu, Nantes, , France
HĂ´pital Archet 1, Nice, , France
HĂ´pital Saint-Louis, Paris, , France
CHU de Toulouse, Toulouse, , France
Marien Hospital DĂźsseldorf, DĂźsseldorf, , Germany
Universität Jena, Medizinische Fakultät, Jena, , Germany
Universität Leipzig, Medizinische Fakultät, Leipzig, , Germany
Klinikum rechts der Isar, MĂźnchen, , Germany
Contact Details
Name: Uwe Platzbecker, MD
Affiliation: Universitätsklinikum Leipzig
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
